{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-028015","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.839802+00:00","generated_at":"2026-05-24T04:55:10.547208+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Leap reports positive sirexatamab CRC data: 32% higher ORR, 3.5mo PFS in high DKK1 patients","bullets":["High DKK1 patients: sirexatamab arm ORR 48% vs 15.8% control; median PFS 9.36 vs 5.88 mo (HR 0.46); OS HR 0.09.","No prior anti-VEGF patients: ORR 55.1% vs 32.6%; median PFS 10.94 vs 8.34 mo (HR 0.59); OS immature.","FY2024 net loss $67.6M ($81.4M in 2023); R&D expenses $57.2M ($73.2M in 2023).","Cash and equivalents $47.2M at Dec 31, 2024; engaged financial advisor for business development.","FL-501 abstract accepted at AACR 2025; preclinical data to be presented April 25-30."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-028015","json":"https://secwatch.observer/filing/0001104659-25-028015.json","markdown":"https://secwatch.observer/filing/0001104659-25-028015.md","text":"https://secwatch.observer/filing/0001104659-25-028015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925028015/0001104659-25-028015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925028015/tm2510101d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:55:10.547208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}